PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

atomoxetine Side Effects

The reactions most often reported to the FDA for atomoxetine (also sold as Strattera), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

3,228
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of atomoxetine come from 3,228 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 3,228 reports to the FDA Adverse Event Reporting System (FAERS) for atomoxetine (Strattera): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

3,228

Reports Mentioning Death

879

27.2% of reports — not proof the medicine caused the death

Hospitalizations

1,203

37.3% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

NAUSEA
431
HEADACHE
407
FATIGUE
401
CONDITION AGGRAVATED
395
HYPERTENSION
388
INSOMNIA
381
VOMITING
381
PAIN
379
ARTHRALGIA
374
ABDOMINAL DISCOMFORT
367
HEPATIC ENZYME INCREASED
367
HYPOAESTHESIA
360
ABDOMINAL PAIN UPPER
350
ALOPECIA
350
GENERAL PHYSICAL HEALTH DETERIORATION
350
GLOSSODYNIA
346
DEPRESSION
343

Who Reports Side Effects

Gender Distribution

Female 1,553 (57%)
Male 1,064 (39%)
Unknown 89

Age Distribution

0-17 582 (25%)
18-44 1,400 (61%)
45-64 237 (10%)
65-74 56 (2%)
75+ 25 (1%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 879 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
ARTHRALGIA 327
GLOSSODYNIA 325
HYPERTENSION 325
GENERAL PHYSICAL HEALTH DETERIORATION 324
HEPATIC ENZYME INCREASED 324
ABDOMINAL DISCOMFORT 319
ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 317
BLOOD CHOLESTEROL INCREASED 317
ALOPECIA 314
ARTHROPATHY 314
HAND DEFORMITY 313
JOINT SWELLING 312
NAIL DISORDER 308
CONDITION AGGRAVATED 293
MATERNAL EXPOSURE DURING PREGNANCY 290
NAUSEA 271
PEMPHIGUS 271
INFUSION RELATED REACTION 270

Reactions in Hospitalization Reports

Top reactions in 1,203 reports where hospitalization was an outcome.

Reaction Reports
CONDITION AGGRAVATED 317
HYPERTENSION 311
HEPATIC ENZYME INCREASED 308
HEADACHE 303
ARTHRALGIA 300
BLOOD CHOLESTEROL INCREASED 299
ABDOMINAL DISCOMFORT 298
ALOPECIA 295
GENERAL PHYSICAL HEALTH DETERIORATION 295
GLOSSODYNIA 294
ARTHROPATHY 293
FATIGUE 293
INSOMNIA 293
JOINT SWELLING 293
GASTROINTESTINAL DISORDER 292
HAND DEFORMITY 292
ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 288

Compare atomoxetine vs acamprosate →

What the FAERS Data Reveals About atomoxetine Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 3,228 voluntary reports linked to atomoxetine and its brand equivalents (Strattera), spanning 2004 through 2025. Of those, 879 (27.2%) listed death as an outcome and 1,203 (37.3%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 57% were female and 39% male; age distribution skews toward 18-44, with 1,400 reports in that bracket. The single most reported reaction is nausea with 431 submissions, followed by headache and fatigue.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.